Voriconazole is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis, among other approved uses. MedsAcross supplies Voriconazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis. • Candidemia in non-neutropenics and other deep tissue Candida infections. • Esophageal candidiasis. • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy
Source: US FDA prescribing information
Voriconazole is an antifungal drug.
Source: US FDA prescribing information
• Dosage in Adults. Infection Loading dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Oral suspension Invasive Aspergillosis 6 mg/kg every 12 hours for the first 24 hours 4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Candidemia in nonneutropenics and other deep tissue Candida infections 3–4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Scedosporiosis and Fusariosis 4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Esophageal Candidiasis Not Evaluated Not Evaluated 200 mg every 12 hours 5 mL every 12 hours o Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours o Hepatic Impairment: Use half the maintenance dose in adult patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) o Renal Impairment: Avoid intravenous administration in adult patients with moderate to severe renal impairment (creatinine clearance <50 mL/min).
Source: US FDA prescribing information
• VFEND is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between VFEND and other azole antifungal agents. Refer to the prescribing information for other azole antifungal agents. • Concomittant use of VFEND with the interacting drugs described and listed below in this section are a guide and not considered a comprehensive list of all possible drugs that may be contraindicated with VFEND. 1.
Source: US FDA prescribing information
• Hepatic Toxicity: Serious hepatic reactions reported. Evaluate liver function tests at start of and during VFEND therapy. • Arrhythmias and QT Prolongation: Correct potassium, magnesium and calcium prior to use, caution patients with proarrhythmic conditions. • Infusion Related Reactions (including anaphylaxis): Stop the infusion. • Visual Disturbances (including optic neuritis and papilledema): Monitor visual function if treatment continues beyond 28 days. • Severe Cutaneous Adverse Reactions: Discontinue for exfoliative cutaneous reactions. • Photosensitivity: Avoid sunlight due to risk of photosensitivity. • Adrenal Dysfunction: Carefully monitor patients receiving VFEND and corticosteroids (via all routes of administration) for adrenal dysfunction both during and after VFEND treatment.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling: Hepatic Toxicity Arrhythmias and QT Prolongation Infusion Related Reactions Visual Disturbances Severe Cutaneous Adverse Reactions Photosensitivity Renal Toxicity • Adult Patients: The most common adverse reactions (incidence ≥2%) were visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, hallucinations.
Source: US FDA prescribing information
Voriconazole is metabolized by cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Therefore, inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively. Voriconazole is a strong inhibitor of CYP3A4, and also inhibits CYP2C19 and CYP2C9. Therefore, voriconazole may increase the plasma concentrations of substances metabolized by these CYP450 isoenzymes. Table 10 and Table 11 provide listings of clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 10 and Table 11 are a guide and not considered a comprehensive list of all possible drugs and herbal products that are contraindicated or may interact with VFEND.
Source: US FDA prescribing information
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C (36°F to 46°F). Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C (36°F to 46°F). VFEND Tablets should be stored at 15°C to 30°C (59°F to 86°F). Do not refrigerate or freeze. VFEND I.V. for Injection unreconstituted vials should be stored at 15°C to 30°C (59°F to 86°F). VFEND Powder for Oral Suspension should be stored at 2°C to 8°C (36°F to 46° F) (in a refrigerator) before reconstitution. The reconstituted suspension should be stored at 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
10 presentations of Voriconazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Voriconazole 200 mg tabletOralGeneric name | — | US FDA | Available on request |
| Voriconazole 50 mg tabletOralGeneric name | — | US FDA | Available on request |
| Voriconazole 10 mg/mL powder for injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Voriconazole 40 mg/mL powder for oral suspensionOral Cold chainGeneric name | — | US FDA | Available on request |
| Vfend 10 mg/mL powder for injectionIntravenous Cold chain | Roerig | US FDA | Available on request |
| Voriconazole 200 mg/20 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Vfend 200 mg tabletOral Cold chain | Roerig | US FDA | Available on request |
| Vfend 40 mg/mL powder for oral suspensionOral Cold chain | Roerig | US FDA | Available on request |
| Voriconazole 200 mg powder for injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Voriconazole 40 mg/mL oral suspensionOral Cold chainGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Voriconazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 10 presentations of Voriconazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Voriconazole, including Vfend.
Yes. The US FDA first approved Voriconazole on 24 May 2002, according to Drugs@FDA.
Yes. Voriconazole has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Voriconazole must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Voriconazole is classified under ATC code J02AC03 (Voriconazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.